Dataset Information


A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria.

ABSTRACT: The emergence of bacteria resistant to vancomycin, often the antibiotic of last resort, poses a major health problem. Vancomycin-resistant bacteria sense a glycopeptide antibiotic challenge and remodel their cell wall precursor peptidoglycan terminus from d-Ala-d-Ala to d-Ala-d-Lac, reducing the binding of vancomycin to its target 1000-fold and accounting for the loss in antimicrobial activity. Here, we report [?[C(?NH)NH]Tpg(4)]vancomycin aglycon designed to exhibit the dual binding to d-Ala-d-Ala and d-Ala-d-Lac needed to reinstate activity against vancomycin-resistant bacteria. Its binding to a model d-Ala-d-Ala ligand was found to be only 2-fold less than vancomycin aglycon and this affinity was maintained with a model d-Ala-d-Lac ligand, representing a 600-fold increase relative to vancomycin aglycon. Accurately reflecting these binding characteristics, it exhibits potent antimicrobial activity against vancomycin-resistant bacteria (MIC = 0.31 ?g/mL, VanA VRE). Thus, a complementary single atom exchange in the vancomycin core structure (O ? NH) to counter the single atom exchange in the cell wall precursors of resistant bacteria (NH ? O) reinstates potent antimicrobial activity and charts a rational path forward for the development of antibiotics for the treatment of vancomycin-resistant bacterial infections.

PROVIDER: S-EPMC3164945 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2006-01-01 | S-EPMC2586002 | BioStudies
2012-01-01 | S-EPMC3262083 | BioStudies
| S-EPMC4376669 | BioStudies
2010-01-01 | S-EPMC2981068 | BioStudies
2009-01-01 | S-EPMC2765482 | BioStudies
2009-01-01 | S-EPMC2702131 | BioStudies
2013-01-01 | S-EPMC3667592 | BioStudies
2014-01-01 | S-EPMC4229326 | BioStudies
2020-01-01 | S-EPMC7007832 | BioStudies
2013-01-01 | S-EPMC3754309 | BioStudies